| Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura M Scully, SR Cataland, F Peyvandi, P Coppo, P Knöbl, ... New England Journal of Medicine 380 (4), 335-346, 2019 | 786 | 2019 |
| Survival and relapse in patients with thrombotic thrombocytopenic purpura JAK Hovinga, SK Vesely, DR Terrell, B Lämmle, JN George Blood, The Journal of the American Society of Hematology 115 (8), 1500-1511, 2010 | 666 | 2010 |
| Caplacizumab for acquired thrombotic thrombocytopenic purpura F Peyvandi, M Scully, JA Kremer Hovinga, S Cataland, P Knöbl, H Wu, ... New England Journal of Medicine 374 (6), 511-522, 2016 | 612 | 2016 |
| Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies M Scully, S Cataland, P Coppo, J De La Rubia, KD Friedman, JK Hovinga, ... Journal of thrombosis and haemostasis 15 (2), 312-322, 2017 | 433 | 2017 |
| The incidence of thrombotic thrombocytopenic purpura‐hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS‐13 deficiency DR Terrell, LA Williams, SK Vesely, B Lämmle, JAK Hovinga, JN George Journal of Thrombosis and Haemostasis 3 (7), 1432-1436, 2005 | 415 | 2005 |
| Thrombotic thrombocytopenic purpura JA Kremer Hovinga, P Coppo, B Lämmle, JL Moake, T Miyata, ... Nature reviews Disease primers 3 (1), 1-17, 2017 | 355 | 2017 |
| ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases M Rieger, PM Mannucci, JAK Hovinga, A Herzog, G Gerstenbauer, ... Blood 106 (4), 1262-1267, 2005 | 351 | 2005 |
| Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies TA Fuchs, JA Kremer Hovinga, D Schatzberg, DD Wagner, B Lämmle Blood, The Journal of the American Society of Hematology 120 (6), 1157-1164, 2012 | 304 | 2012 |
| Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015 EE Page, JA Kremer Hovinga, DR Terrell, SK Vesely, JN George Blood advances 1 (10), 590-600, 2017 | 274 | 2017 |
| Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features JA Reese, DS Muthurajah, JAK Hovinga, SK Vesely, DR Terrell, ... Pediatric blood & cancer 60 (10), 1676-1682, 2013 | 269 | 2013 |
| Thrombotic thrombocytopenic purpura B Lämmle, JAK Hovinga, L Alberio Journal of Thrombosis and Haemostasis 3 (8), 1663-1675, 2005 | 257 | 2005 |
| Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura M Scully, P Knöbl, K Kentouche, L Rice, J Windyga, R Schneppenheim, ... Blood, The Journal of the American Society of Hematology 130 (19), 2055-2063, 2017 | 252 | 2017 |
| IgG subclass distribution of anti‐ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura S Ferrari, GC Mudde, M Rieger, A Veyradier, JAK Hovinga, F Scheiflinger Journal of Thrombosis and Haemostasis 7 (10), 1703-1710, 2009 | 209 | 2009 |
| Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura CC Deford, JA Reese, LH Schwartz, JJ Perdue, JA Kremer Hovinga, ... Blood, The Journal of the American Society of Hematology 122 (12), 2023-2029, 2013 | 204 | 2013 |
| ADAMTS‐13, von Willebrand factor and related parameters in severe sepsis and septic shock JAK Hovinga, S Zeerleder, P Kessler, TR De Wit, JA Van Mourik, CE Hack, ... Journal of Thrombosis and Haemostasis 5 (11), 2284-2290, 2007 | 196 | 2007 |
| Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin JD Studt, JAK Hovinga, G Antoine, M Hermann, M Rieger, F Scheiflinger, ... Blood 105 (2), 542-544, 2005 | 196 | 2005 |
| Reevaluation of the incidence of thromboembolic complications in congenital factor XII deficiency S Zeerleder, M Schloesser, M Redondo, WA Wuillemin, W Engel, ... Thrombosis and haemostasis 82 (10), 1240-1246, 1999 | 187 | 1999 |
| Recombinant ADAMTS13 normalizes von Willebrand factor‐cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies B Plaimauer, JAK Hovinga, C Juno, MJ Wolfsegger, S Skalicky, ... journal of Thrombosis and Haemostasis 9 (5), 936-944, 2011 | 180 | 2011 |
| Impaired DNase1‐mediated degradation of neutrophil extracellular traps is associated with acute thrombotic microangiopathies M Jimenez‐Alcazar, M Napirei, R Panda, EC Köhler, JAK Hovinga, ... Journal of Thrombosis and Haemostasis 13 (5), 732-742, 2015 | 152 | 2015 |
| Plasma DNA is elevated in patients with deep vein thrombosis JA Diaz, TA Fuchs, TO Jackson, JAK Hovinga, B Lämmle, PK Henke, ... Journal of Vascular Surgery: Venous and Lymphatic Disorders 1 (4), 341-348. e1, 2013 | 151 | 2013 |
